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Major efforts to sequence cancer genomes are now occurring throughout the world[1, 2]. Though
the emerging data from these studies are illuminating, their reconciliation with epidemiologic and
clinical observations poses a major challenge[3]. In the current study, we provide a novel mathe-
matical model that begins to address this challenge. We model tumors as a discrete time branching
process[4] that starts with a single driver mutation and proceeds as each new driver mutation leads
to a slightly increased rate of clonal expansion. Using the model, we observe tremendous variation
in the rate of tumor development – providing an understanding of the heterogeneity in tumor sizes
and development times that have been observed by epidemiologists and clinicians. Furthermore,
the model provides a simple formula for the number of driver mutations as a function of the total
number of mutations in the tumor. Finally, when applied to recent experimental data, the model
allows us to calculate, for the first time, the actual selective advantage provided by typical somatic
mutations in human tumors in situ. This selective advantage is surprisingly small, 0.005 ± 0.0005,
and has major implications for experimental cancer research.
It is now well-accepted that virtually all cancers re-
sult from the accumulated mutations in genes that in-
crease the fitness of a tumor cell over that of the cells
that surround it[5, 6]. As a result of advances in technol-
ogy and bioinformatics, it has recently become possible
to determine the entire compendium of mutant genes in
a tumor[7, 8, 9, 10, 34, 36]. Studies to date have revealed
a complex genome, with ∼ 40− 80 amino-acid changing
mutations present in a typical solid tumor[9, 10, 34, 36].
For low frequency mutations, it is difficult to distinguish
”driver mutations” – defined as those that confer a se-
lective growth advantage to the cell – from ”passenger
mutations”[6, 13, 14]. Passenger mutations are defined
as those which do not alter fitness but occurred in a cell
that coincidentally or subsequently acquired a driver mu-
tation, and are therefore found in every cell with that
driver mutation. It is believed that only a small fraction
of the total mutations in a tumor are driver mutations,
but new, quantitative models are clearly needed to help
interpret the significance of the mutational data and to
put them into the perspective of other lines of cancer
research investigation.
In most previous models of tumor evolution, mutations
accumulate in cell populations of constant size[15, 16, 17]
or of variable size, but the models take into account only
one or two mutations[18, 19, 20, 21, 22]. In our new
model, we assume that each new driver mutation leads
to a slightly faster tumor growth rate. This model is as
simple as possible as the analytical results depend on only
three parameters: the average driver mutation rate, the
average selective advantage associated with driver muta-
tions, and the average cell division time.
Tumors are initiated by the first genetic alteration that
provides a relative fitness advantage. In the case of typi-
cal leukemias, this would represent the first alteration of
an oncogene, such as a translocation between BCR and
ABL. In the case of solid tumors, the mutation that ini-
tiated the process might actually be the second ”hit in
a tumor suppressor gene – the first hit affects one allele,
without causing a growth change, while the second hit, in
the opposite allele, leaves the cell without any functional
suppressor, in accord with the two-hit hypothesis[23]. It
is important to point out that we are modeling tumor
progression, not initiation[15, 16], because progression is
rate-limiting for cancer mortality – it generally requires
three or more decades for metastatic cancers to develop
from initiated cells in humans.
Our first goal is to characterize the times at which suc-
cessive driver mutations arise in a tumor of growing size.
We have employed a discrete time branching process in
this model because it makes the numerical simulations
feasible. In a discrete time process, all cell divisions are
synchronized. We present analytic formulas for this dis-
crete time branching process and analogous formulas for
the continuous time case (in Appendix G) when possible.
At each time step, a cell can either divide or differentiate,
senesce, or die. In the context of tumor expansion, there
is no difference between differentiation, death, and senes-
cence, as none of these processes will result in a greater
number of tumor cells than present prior to that time
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FIG. 1: Variability in tumor progression. Number of
cells with a given number of driver mutations versus the age
of the tumor. Six different realizations of the same stochastic
process with the same parameter values are shown, corre-
sponding to tumor growth in six ’patients’. The process is
initiated with a single surviving founder cell with one driver
mutation. The times at which subsequent driver mutations
arose varied widely among ’patients’. After initial stochas-
tic fluctuations, each new mutant lineage grew exponentially.
The overall dynamics of tumor growth are greatly affected by
the random time of the appearance of new mutants with sur-
viving lineages. Parameter values: mutation rate u = 10−5,
selective advantage s = 0.5% and generation time T = 3 days.
step. We assume that driver mutations reduce the prob-
ability that the cell will take this second course, i.e., that
it will differentiate, die, or senesce, henceforth grouped
as ”stagnate”. A cell with k driver mutations therefore
has a stagnation probability dk = 12 (1−s)k. The division
probability is bk = 1−dk. The parameter s characterizes
the (average) selective advantage of each driver mutation
that occurs following the initiating mutation.
When a cell divides, one of the daughter cells can re-
ceive an additional driver mutation with probability u.
The point mutation rate per base per cell division is
∼ 5× 10−10. There is a finite number of tumor suppres-
sor genes and oncogenes that can be mutated at each
time point and lead to driver mutations. We conserva-
tively estimate that there are ∼ 100 tumor suppressor
genes and ∼ 100 oncogenes in a human cell, and that on
average each tumor suppressor gene can be inactivated
by mutation at ∼ 200 positions and each oncogene can
be activated in ∼ 10 positions. There are thus a total
of ∼ 21, 000 positions in the genome that could become
driver mutations. As the rate of chromosome loss in tu-
mors is much higher than the rate of point mutation[15],
a single point mutation is rate limiting for inactivation
of tumor suppressor genes. The driver mutation rate is
therefore ∼ 10−5 per cell division (≈ 21000× 5× 10−10).
Our theory can accommodate any realistic mutation rate
and the major numerical results are only weakly affected
by varying the mutation rate within a reasonable range.
Experimental evidence suggests that tumor cells di-
vide about once every three days in glioblastoma
multiforme[24] and once every four days in colorectal
cancers[25]. Incorporating these division times into the
simulations provided by our model leads to the dramatic
results presented in Fig. 1. Though the same parame-
ter values – u = 10−5 and s = 0.5% – were used for
each simulation, there was an enormous variation in the
times required for disease progression. For example, in
’Patient 1’, the second driver mutation had not occurred
within 20 years following tumor initiation and the size
of the tumor remained small (micrograms, representing
< 105 cells). In contrast, in ’Patient 6’, the second driver
mutation occurred after only two years and by 20 years
the tumor would weigh kilograms (1012 cells), with the
most common cell types in the tumor having three or
four driver mutations. ’Patients 2 to 5’ had progression
rates between these two extreme cases.
The results in Fig. 1 provide insights into the nature
of tumor development in patients with familial adenoma-
tous polyposis (FAP)[26]. If untreated (by colectomy),
these patients develop adenomas while teenagers, but do
not develop cancers until their fourth or fifth decades of
life, by which time there are thousands of tumors per
patient. Each of these thousands of tumors represents
a process that is roughly similar to one of the processes
in Fig. 1. Hence it is likely that at least one of them
will progress relatively fast, as in ’Patient 6’ in Fig. 1.
A patient without FAP who has initiated one polyp has
only a ∼ 0.001 probability of having a cell in that polyp
that has accumulated ten driver mutations, even after 20
years. On the other hand, a patient that has initiated
1000 polyps has a 0.63 probability of having a cell in
at least one polyp with ten driver mutations during the
same time period. This quantitatively explains (i) why
the polyps in an individual patient with FAP are so het-
erogeneous in size and (ii) why cancers are so much more
common in FAP patients than in the general population,
despite the fact that the inherited mutation affects only
tumor initiation and does not directly affect tumor pro-
gression.
We can calculate the average time between the ap-
pearance of successful cell lineages (Fig. 2). Not all new
mutants are successful, because stochastic fluctuations
can lead to the extinction of a lineage. The lineage of a
cell with k driver mutations survives only with a prob-
ability approximately 1 − dk/bk ≈ 2sk. Assuming that
u ks 1, the average time between the first successful
cell with k and the first successful cell with k + 1 driver
mutations is given by
τk =
T
ks
log
2ks
u
. (1)
3FIG. 2: Schematic representation of waves of clonal
expansions. An illustration of a sequence of clonal expan-
sions of cells with k =1, 2, 3 or 4 driver mutations is shown.
Here τ1 is the average time it takes the lineage of the founder
cell to produce a successful cell with two driver mutations.
Similarly, τk is the average time between the appearance of
cells with k and k+ 1 mutations. Equation (1) gives a simple
formula for these waiting times, which shows that subsequent
driver mutations appear faster and faster. The cumulative
time to have k driver mutations grows with the logarithm of
k.
The introduction of subsequent driver mutations be-
comes faster and faster. (See Appendices C and D) For
example, for u = 10−5, s = 10−2 and T = 4 days it
takes on average 8.3 years until the 2nd driver mutation
emerges, but only 4.5 more years until the 3rd driver mu-
tation emerges. The cumulative time to have k mutations
grows logarithmically with k. See Table 1 for additional
numerical examples.
In contrast to driver mutations, passenger mutations
do not confer a fitness advantage, and they do not modify
tumor growth rates. We find that the average number of
passenger mutations, n(t), present in a tumor cell after
t days is proportional to t, that is n(t) = vt/T , where v
is the rate of acquisition of neutral mutations. In fact, v
is the product of the point mutation rate per base pair
and the number of base pairs analyzed. This simple re-
lation has been used to analyze experimental results by
providing estimates for relevant time scales[25].
Combining our results for driver and passenger muta-
tions, we can derive a formula for the number of passen-
gers that are expected in a tumor that has accumulated
k driver mutations (see Appendix F)
n =
v
2s
log
4ks2
u2
log k. (2)
Here n is the number of passengers that were present in
the last cell that clonally expanded. Equation (2) can be
most easily applied to tumors in tissues in which there
was not much cell division prior to the tumor initiation,
as otherwise a difficult estimate of the expected number
of passengers that accumulated in a precursor cell prior
to tumor initiation would be required.
To test the validity of this model, we tested it on
two tumor types that have been extensively analyzed.
Neither the astrocytic precursor cells that give rise
to glioblastoma multiforme (GBM)[27] nor the pan-
creatic duct epithelial cells that give rise to pancre-
s u τ1 τ2 τ3 τ4
0.1% 10−5 58.0 32.8 23.4 18.3
0.5% 10−5 15.1 8.3 5.8 4.5
1% 10−5 8.3 4.5 3.2 2.5
2% 10−5 4.5 2.5 1.7 1.3
10% 10−5 1.1 0.6 0.4 0.3
1% 10−6 10.8 5.8 4.0 3.1
1% 5 · 10−6 9.1 4.9 3.4 2.7
1% 10−5 8.3 4.5 3.2 2.5
1% 2 · 10−5 7.6 4.2 2.9 2.3
1% 10−4 5.8 3.3 2.3 1.8
TABLE I: Times between clonal waves Numerical values
for the average time τk (in years) between the first successful
cell with k and k + 1 driver mutations, for different values
of the selective advantage s and the mutation rate u. Cells
divide every T = 4 days. The table shows that changing the
selective advantage of drivers has a large effect on the waiting
times, while changing the driver mutation rate has a relatively
small effect.
atic adenocarcinomas[28] divide much prior to tumor
initiation[29, 30]. Therefore the data on both tumors
should be suitable for our analysis. Parsons et al.[34] se-
quenced 20,661 protein coding genes in a series of GBM
tumors and found a total of 713 somatic mutations in the
14 samples that are depicted in Fig. 3. Similarly, Jones et
al.[36] sequenced the same genes in a series of pancreatic
adenocarcinomas, finding a total of 562 somatic muta-
tions in the 9 primary tumors graphed in Fig. 3. In both
cases, we classified missense mutations as drivers if they
were classified as such by the CHASM algorithm at false
discovery rate (FDR) 0.2[37] (see Appendices H and I).
We also considered all nonsense mutations, out-of-frame
insertions or deletions (INDELs) and splice-site changes
as drivers because these generally lead to inactivation of
the protein products[36]. All other somatic mutations
were considered to be passengers.
From Fig. 3a and b, it is clear that the experimen-
tal results on both GBM and pancreatic cancers were
in good accord with the predictions of equation (2). A
critical test of the model can be performed by compari-
son of the best-fit parameters governing each tumor type.
It is expected that the average selective advantage of a
driver mutation should be similar across all tumor types
given that the pathways through which these mutations
act overlap to a considerable degree. Setting the driver
mutation rate to be u = 10−5 and fitting equation (2)
to the GBM data using least squares analysis, we found
that the optimum fit was given by s = 0.0048 ± 0.0004.
Remarkably, using the same mutation rate in pancreatic
cancers, we find that the best fit is given by a nearly
identical s = 0.0050± 0.0005. This consistency not only
provides support for the model but also provides evi-
dence that the average selective advantage of a driver is
s ≈ 0.5%. For u = 10−6 and u = 10−4, we get s ≈ 0.65%
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FIG. 3: Comparison of clinical mutation data and the-
ory. Our theory provides an estimate for how the number of
passenger mutations found in a tumor is related to the number
of driver mutations. Here we show a comparison of equation
(2) (green line) with genomic data from glioblastoma multi-
forme (GBM) and pancreatic cancer. We also compare our
analytic result with computer simulations. Parameter values
used in equation (2) and computer simulations were s = 0.5%
and u = 10−5. a, Equation (2) (green line) fitted to GBM
data from 14 patients. b, Equation (2) (green line) fitted
to pancreatic cancer data from 9 patients. c, Comparison of
computer simulations and equation (2). For each k between
2 and 10, the number of passengers that were brought along
with the last driver in 10 tumors with k drivers is plotted.
d, Comparison between computer simulations and equation
(2) for selective advantage of the k-th driver, sk, taken from
a Gaussian distribution with mean s and standard deviation
σ = s/2. For each k between 2 and 10, the number of passen-
gers that were brought along with the last driver in 10 tumors
with k drivers is plotted.
and s ≈ 0.32%, respectively. The fact that these esti-
mates are not strongly dependent on the mutation rate
supports the robustness of the model.
In Beerenwinkel et al.[32], we have previously mod-
eled tumors which are slowly expanding due to some con-
straint, using a Wright-Fisher process. The new results
are considerably different. For example, Beerenwinkel et
al. found that the ”waiting time required to accumu-
late k driver mutations was proportional to k, while in
the new model the waiting time depends on the loga-
rithm of k. Our formula for the waiting time provides a
much better explanation for the long initial stages in the
adenoma-carcinoma sequence[25].
Like all models, ours incorporates limiting assump-
tions. However, many of these assumptions can be loos-
ened without changing the key conclusions. For exam-
ple, we assumed that the selective advantage of every
driver was the same. We have tested whether our for-
mulas still hold in a setting wherein the selective advan-
tage of the k-th driver is sk, and sk’s are drawn from
a Gaussian distribution with mean s and standard de-
viation σ = s/2. The simulations were still in excellent
agreement with equation (2) (Fig. 3d). Similarly, we as-
sumed that the time between cell divisions (generation
time T) was constant. Nevertheless, equation (2), which
gives the relationship between drivers and passengers, is
derived without any specification of time between cell di-
visions. Consequently, this formula is not affected by the
possible change in T. Finally, there could be a finite car-
rying capacity for each mutant lineage. In other words,
cells with one driver mutation may only grow up to a
certain size, and the tumor may only grow further if it
accumulates an extra mutation, allowing cells with two
mutations to grow until they reach their carrying capac-
ity and so on. It is reasonable to assume that the carrying
capacities of each class would be much larger than 1/u,
which is approximately the number of cells with k mu-
tations needed to produce a cell with k + 1 mutation.
Thus, the times at which new mutations arise would not
be much affected by this potential confounding factor.
Given the true complexity of cancer, our model is de-
liberately oversimplified. Despite its simplicity, however,
it captures some essential characteristics of the genetic
complexity underlying tumor growth. Simple models
have already been very successful in providing important
insights into cancer. Notable examples include Knud-
son’s two hit model[23] and Armitage-Doll’s multi-hit
hypothesis[33]. The model described here represents the
first attempt to provide analytical insights into the re-
lationship between drivers and passengers in tumor pro-
gression and will hopefully be similarly stimulating. One
of the major conclusions, i.e., that the selective growth
advantage afforded by the mutations that drive tumor
progression is very small (∼ 0.5%), has major implica-
tions for understanding tumor evolution. For example,
it shows how difficult it will be to create valid in vitro
models to test such mutations on tumor growth; selec-
tive growth advantages of 0.5% are nearly impossible to
discern in cell culture over short time periods. And it
explains why so many driver mutations are needed to
form an advanced malignancy within the lifetime of an
individual.
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APPENDIX A: SIMULATIONS
We model tumor progression with a discrete time
Galton-Watson branching process. In our model, at each
time step a cell with j mutations (or j-cell) either di-
vides into two cells, which occurs with probability bj , or
5dies with probability dj , where bj + dj = 1. In addition,
at every division, one of the daughter cells can acquire
an additional mutation with probability u. The process
is initiated by a single cell with one mutation. We set
dj = 12 (1 − s)j , so that additional mutations reduce the
probability of cell death.
In simulations, we track the numbers of cells with j
mutations, Nj , for j = 1, . . . , p, rather than the faith
of each individual cell. We increase the efficiency of the
computation by sampling from the multinomial distribu-
tion at each time step. Let Nj(t) be the number of cells
with j mutations at time t. Then the number of j-cells
that will give birth to an identical daughter cell, Bj , the
number of j-cells that will die, Dj , and the number of j-
cells that will give birth to a cell with an extra mutation,
Mj , are sampled from the multinomial distribution with
Prob[(Bj , Dj ,Mj) = (n1, n2, n3)] =
=
Nj(t)!
n1!n2!n3!
[bj(1− u)]n1dn2j (bju)n3 ,
(A1)
for n1 + n2 + n3 = Nj(t). Then,
Nj(t+ 1) = Nj(t) +Bj −Dj +Mj−1. (A2)
Note that in this model, all cell divisions and cell deaths
occur simultaneously at each time step. One could define
an analogous continuous time model, with a very simi-
lar behavior. Simulations of the continuous time model,
however, are much less efficient, since the updates occur
at smaller and smaller time steps as the population size
grows.
APPENDIX B: AVERAGE NUMBER OF j-CELLS
In this section, we derive an analytical expression for
the average abundance of cells with j mutations after t
time steps in a Galton-Watson process. Since the popu-
lation is initiated by a single cell, it might go extinct due
to random events. If the population survives, it exhibits
waves of clonal expansions.
Let xj(n) denote the average number of j-cells after
n time steps. The averages xj are evolving according to
the following system of difference equations:
x1(n+ 1) = b1(2− u)x1(n)
xj(n+ 1) = bj(2− u)xj(n) + bj−1uxj−1(n), j > 1,
(B1)
with initial conditions x1(0) = 1 and xj(0) = 0 for j >
1. This system of infinite number of linear differential
equations can be solved exactly. For a single initial 1-
cell, we obtain
x1(n) = [b1(2− u)]n. (B2)
From this, we can find the solution for 2-cells and so on,
arriving at the formula for the expected number of j-cells
after n time steps
xj(n) = uj−1(2− u)n−j+1
j−1∏
k=1
bk
j∑
k=1
bnk∏j
q=1,q 6=k bk − bq
.
(B3)
The expression (B3) is the exact formula for the average
number of cells with j mutations in our process, which
holds for any choice of selective advantage s and mutation
rate u between 0 and 1. This can be easily proven by
substituting the solution (B3) into the equations (B1).
This formula can be approximated by a simpler analytical
expression in the small s and u  s limit, which are
reasonable assumptions for tumor progression.
Since bk’s are strictly increasing with k, xj(t) can be
well approximated by its leading term behavior,
xj(t) = aj [bj(2− u)]t, (B4)
with
aj =
(
u
2− u
)j−1(j−1∏
k=1
bk
bj − bk
)
,
for all times t for which e−st  1. In the weak selection
limit, s  1/j and in the low mutation limit u  1, we
can approximate (1−s)j ≈ 1− js and (2−u) ≈ 2, to get
aj =
1
(j − 1)!
( u
2s
)j−1
. (B5)
In addition, if u s we have [bj(2−u)]t ≈ [2−(1−s)j ]t.
leading to the expression for the average abundance of
j-cells after t time steps
xj(t) =
1
(j − 1)!
( u
2s
)j−1 [
2− (1− s)j]t . (B6)
Note that in the last equation we do not approximate
(1 − s)j with 1 − js, since for large values of t this ap-
proximation would lead to significant errors.
Formulas (B3) and (B6) are averages calculated consid-
ering both trajectories of extinction and non-extinction.
The average abundance of cells with j mutations after t
time steps, conditioned on non-extinction, is given by
Xj(t) =
xj(t)
1− q(t) , (B7)
where q(t) is the is the probability that the population
goes extinct by t. We note that extinction is most likely
an early event in the process and that it occurs when
the population consists almost entirely of 1-cells. Thus
we can approximate q(t) by eventual extinction proba-
bility of a population initiated by a single cell with one
mutation, in a process with no mutation
q(t) ≈ q1. (B8)
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FIG. 4: Average number of cells with j mutations, as pre-
dicted by formula (B6). Parameter values are s = 0.01,
u = 10−5 and T = 4 days.
In a process with no mutation, the probability that a
population initiated by a single cell with one mutation
goes extinct is given by
q1 =
d1
1− d1 =
1− s
1 + s
≈ 1− 2s (B9)
where the last approximation is valid in the small s limit.
Finally we have the expression for the average number
of cells with j mutations, conditioned on non-extinction,
Xj(t) =
1
2s(j − 1)!
( u
2s
)j−1
(2− (1− s)j)t. (B10)
The average numbers of cells with j mutations for
j = 1, . . . , 20, as predicted by formula (B10), are shown
in Fig. S1. In Fig. S2, we plot the excellent agreement
between these predicted averages and simulations. How-
ever, we note that due to large fluctuations in the num-
bers of cells with j mutations at time t (see Fig. 1 from
the main text), the averages (B10) are not that useful
for describing the dynamics of the process, as they are
biased towards realizations with large numbers of cells.
For example, in Fig. S1 we see that the average number
of cells with 2 mutations is 1 after about 2 years. On the
other hand, simulation suggest that the average time to
the first successful cell with 2 mutations is approximately
8 years for the parameter values from Fig. S1.
APPENDIX C: THE RATE OF INTRODUCTION
OF NEW MUTANTS
Simulations of our Galton-Watson process suggest that
the times at which a new mutant with a surviving lineage
is produced have a significant effect on the dynamics of
the process. In this section we give an approximation for
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FIG. 5: Average number of cells with j mutations, comparison
of formula (B6) and simulations. Parameter values are s =
0.01, u = 10−5, T = 4 days and t = 9 years.
the average time it takes the first j-cell with surviving
lineage to produce a (j + 1)-cell with surviving lineage.
The average number of j-cells grows as xj =
1
1−qj [bj(2− u)]τ , where τ is the time measured from the
appearance of the first successful j-cell and qj =
dj
1−dj
is the extinction probability of j-cells. New (j + 1)-cells
with surviving lineages appear at rate (1 − qj+1)ubjxj ,
and we approximate the time of the appearance of the
first (j + 1) cell with surviving lineage, τj , by the time
when the total rate reaches one cell, that is
τj∑
k=1
1− qj+1
1− qj ubj [bj(2− u)]
k = 1 (C1)
This leads to
τj =
log
[
1 + 1−qjubj(1−qj+1)
(
1− 1bj(2−u)
)]
log[bj(2− u)] . (C2)
We consider selection and mutation rate to be small
enough, u 1 and s 1, so log[bj(2−u)] ≈ js. We also
assume js  1 so we can approximate (2 − (1 − s)j) ≈
1 + js, and thus 1 − 1/[bj(2 − u)] ≈ js . In these limits
we also have 1−qjubj(1−qj+1) ≈
2j
u(j+1) . Now we can write
τj =
log 2j
2s
(j+1)u
js
. (C3)
We can further simplify this formula by noting that
j
j+1 ≈ 1 to obtain
τj =
log 2jsu
js
. (C4)
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FIG. 6: Speed of introduction of new mutants: comparison of
formula and simulation. Comparison of predicted and simu-
lated average time it takes the lineage of the first successful
j-mutant to produce the first successful (j+1)-mutant, τj , for
different values of selective advantage s. Circles correspond
to times obtained from simulations, and lines correspond to
formula (C4). Parameter values are u = 10−5 and T = 4
days.
If, in addition, we assume that generation time is T , we
get
τj =
T
js
log
2js
u
. (C5)
The excellent agreement between formula (C4) and
simulations is shown if Fig. S3.
APPENDIX D: WAITING TIME TO k
MUTATIONS
We also derive a formula for the average time it takes
for the first successful k-mutant to be produced in the
process, tk, by assuming
tk =
k−1∑
j=1
τj . (D1)
Substituting expression (C4) for τj , we arrive at
tk =
k−1∑
j=1
log 2jsu
js
. (D2)
We approximate the last sum with an integral as
tk =
∫ k
1
log 2jsu
js
. (D3)
which then leads to the following formula for waiting time
tk =
T
2s
log
4ks2
u2
log k. (D4)
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FIG. 7: Waiting time to k mutations. Comparison of pre-
dicted and simulated average time it takes for the first suc-
cessful k-mutant to be produced in the process for different
values of selective advantage s. Circles correspond to times
obtained from simulations, and lines correspond to formula
(D4). Parameter values are u = 10−5 and T = 4 days.
The comparison between formula (D4) and simulations
is shown if Fig. S4.
APPENDIX E: PASSENGER MUTATIONS
Suppose now that we have a model in which there are
two types of mutations: drivers, which confer selective
advantage as before, and passengers, which have no influ-
ence on the fitness of the cell. If a cell with n passenger
mutations divides, then each of the daughter cells can
have one additional passenger mutations with probabil-
ity v. Since passenger mutation do not affect the fitness
of the cell, after t time steps, each cell still alive has the
probability (
t
n
)
vn(1− v)t−n (E1)
to have n passenger mutations. It follows that the aver-
age number of passenger mutations present in the neo-
plastic cell population after t time steps is
n(t) = tv. (E2)
Note that a crucial condition for (E1) to be valid is that
the time increments must be constant, that is by time
t each cell undergoes t cell divisions. This condition is
not satisfied generally in continuous time branching pro-
cesses. Note also that, while in our model only one of the
two offsprings can acquire a driver mutation in a cell divi-
sion, both of them can acquire a passenger mutation. The
reason is that we safely neglected the possibility of new
driver mutations in both offsprings, since that is roughly
8u/2 = 0.5 × 10−5 times less probable than acquiring a
driver mutations in only one of the offsprings.
APPENDIX F: DRIVERS VS PASSENGERS
Combining our results (D4) and (E2) for driver and
passenger mutations, we give a formula for the number of
passengers we expect to find in a tumor that accumulated
k driver mutations
n =
v
2s
log
4ks2
u2
log k. (F1)
Note that n is the number of passengers that were
present in the last cell that clonally expanded. It is these
passenger mutations that can be detected experimentally.
Formula (F1) can only be applied to tumors in tissues in
which there was not much cell division prior to tumori-
genesis.
APPENDIX G: CONTINUOUS TIME FORMULAS
In this section we define a similar continuous time
model and list the above analytical results in this set-
ting. As before, we start with one cell with one driver
mutation. In a short time interval ∆t, a cell with j driver
mutations can divide with probability bj∆t and die with
probability dj∆t.
Let xj(t) be the expected number of cells with j muta-
tions alive at time t. The population is evolving accord-
ing to the differential equations:
dx1
dt
= [b1(1− u)− d1]x1,
dxj
dt
= [bj(1− u)− dj ]xj + bj−1uxj−1 for j ≥ 2,
subject to the initial conditions x1(0) = 1 and xj(0) = 0
for j ≥ 2. This system can be solved analytically and the
exact solution is
xj =
j−1∏
l=1
blu
j∑
k=1
erkt∏j
q=1,q 6=k((bk − bq)(1− u) + dq − dk)
(G1)
with rk = bk(1− u)− dk.
In order to model tumor progression, let us specify
the rates bj and dj . Perhaps the simplest choice is to as-
sign the same fitness advantage to each driver mutations,
that is have a j dependent division rate bj = 1 + sj,
and constant death rate dj = 1. The main problem
with this choice is, that when substituting them into
the general formula (G1), it turns out that the aver-
age number of cells becomes infinite at the finite time
t∗ = − log u/[s(1 − u)]. The underlying reason for this
blowup is the presence of an infinite number of cell types.
This artifact can be easily avoided by making each mu-
tation decrease the death rate of cells, that is to define
dj = (1 − s)j , and to make the division rate constant
bj = 1. The population always remains finite in this ver-
sion of the model. Fitter cells, however, have shorter gen-
eration times than less fit cells. Hence, at any given time
t, different cells may have undergone different numbers
of cell divisions. As a consequence, the expected num-
ber of neutral mutations is not the same for all cells (in
fact it is positively correlated with the number of driver
mutations), hence we do not have a simple relationship
between drivers and passengers as in the discrete time
case. For this reason we propose the following definition
instead.
We define a continuous time branching process similar
to the discrete one we use in the paper. In this process,
an event (division or death of a cell) occurs at rate 1/T . If
an event occurs to a cell with j mutations, then it is death
with probability 12 (1 − s)j and division with probability
1 − 12 (1 − s)j . Thus, bj = (1 − 12 (1 − s)j)/T and dj =
1
2T (1− s)j .
In this case, the time between the appearance of the
first successful j-cell and the appearance of the first suc-
cessful (j + 1) cell, τj is given by
τj =
T
js
log
2js
uT
. (G2)
The waiting time to the first successful k mutation is
tk =
T
2s
log
4ks2
(uT )2
log k. (G3)
Since the times between successive divisions of a single
cell line are constant on average, we can use formula (E2)
for passenger mutations, in order to get the following
formula for the number of passengers as a function of the
number of drivers
n =
v
2s
log
4ks2
(uT )2
log k. (G4)
APPENDIX H: MUTATION DATA
Parsons et al. [34] sequenced 20,661 protein coding
genes in 22 human glioblastoma multiforme GBM tumor
samples using polymerase chain reaction (PCR) sequence
analysis. 7 samples were extracted directly from patient
tumors and 15 samples were passaged in nude mice as
xenografts. All samples were matched with normal tissue
from the same patient in order to exclude germline mu-
tations. Analysis of the identified somatic mutations re-
vealed that one tumor (Br27P), form a patient previously
treated with radiation therapy and temozolomide, had 17
times as many alterations as any of the other 21 patients,
consistent with previous observations of a hypermuta-
tion phenotype in glioma samples of patients treated with
9Gene Mutation CHASM score P -value
CDKN2A H98P 0.024 0.0004
CDKN2A L63V 0.096 0.0004
TP53 C275Y 0.028 0.0004
TP53 G266V 0.024 0.0004
TP53 H179R 0.152 0.0004
TP53 I255N 0.024 0.0004
TP53 L257P 0.048 0.0004
TP53* R175H 0.078 0.0004
TP53* R248W 0.114 0.0004
TP53 R282W 0.126 0.0004
TP53 S241F 0.044 0.0004
TP53* V217G 0.144 0.0004
TP53* Y234C 0.022 0.0004
NEK8 A197P 0.268 0.0008
PIK3CG R839C 0.258 0.0008
SMAD4* C363R 0.240 0.0008
TP53 D208V 0.240 0.0008
TP53* K120R 0.262 0.0008
TP53 T155P 0.202 0.0008
MAPT G333V 0.322 0.0021
DGKA V379I 0.336 0.0025
STK33 F323L 0.342 0.0025
FLJ25006 S196L 0.392 0.0038
PRDM5* V85I 0.396 0.0038
TP53 L344P 0.406 0.0050
TTK D697Y 0.426 0.0063
NFATC3* G451R 0.464 0.0067
PRKCG* P524R 0.444 0.0067
CMAS I275R 0.474 0.0071
KRAS* G12D 0.474 0.0071
PCDHB2 A323V 0.476 0.0071
STN2 I590S 0.474 0.0071
SMAD4 Y95S 0.496 0.0092
TABLE II: Driver mutations predicted by CHASM. Missense
mutations found in 24 pancreatic cancer samples from Jones
et al.[36] which are classified as drivers by CHASM at FDR of
0.2, shown with their associated Random Forest scores and P
values. (* denotes the missense mutations classified as drivers
in the 9 samples used in our analysis.)
temozolomide [35]. After removing Br27P from consider-
ation, it was found that the 6 DNA samples extracted di-
rectly from patient tumors had smaller numbers of muta-
tions than those obtained from xenografts, likely because
of the masking effect of nonneoplastic cells in the former
[25]. For this reason we chose only to focus on the muta-
tion data which were taken from xenografts. From the 15
xenograft samples, we excluded one sample(Br04X) be-
cause it was taken from a recurrent GBM which may have
had prior radiation therapy or chemotherapy, leaving us
with 14 samples we used for our study.
Similarly, Jones et al. [36] sequenced 20,661 protein
coding genes in 24 pancreatic cancers. 10 samples were
passaged in nude mice as xenografts and 14 in cell lines.
For the purpose of our study, we discarded the samples
taken from metastases, and used the 9 samples which
were taken from primary tumors as xenografts, for con-
sistency with GBM data.
APPENDIX I: CHASM ANALYSIS OF MISSENSE
MUTATIONS FOUND IN PANCREATIC
CANCERS
Carter et al. [37] used CHASM algorithm to analyse
GBM missense mutations found in 22 GBM samples from
Parsons et al [34] and classify them as either drivers or
passengers. We carried out CHASM analysis of missense
mutations found in the original 24 pancreatic cancer sam-
ples [36]. 33 mutations that were classified as drivers by
the CHASM algorithm at false discovery rate (FDR) 0.2
are shown in Table S1.
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